We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Stay up to date on the topics that matter to you

Development of a Robust Reporter-based T cell Activation Assay for Therapeutic Biologics in Immunotherapy

Poster

Published: October 9, 2015

Development of a Robust Reporter-based T cell Activation Assay for Therapeutic Biologics in Immunotherapy content piece image

Jurkat T-cells stably expressing luciferase reporter driven by IL2 promoter or NFAT-RE, are used as effector cells. Tumor cell lines endogenously expressing cancer antigen are used as antigen presenting cells (APC). By co-cultivating the two cell lines in the presence of CD3 bispecific antibody, TCR/CD3 is activated in Jurkat effector cells. Luciferase activity is up regulated through IL-2 promoter or NFAT-RE activation.